Sphere Bio has expanded its distribution network across Asia-Pacific, appointing five new partners to support regional demand for its single-cell analysis platforms.

The company, which specialises in picodroplet-based microfluidics, confirmed new partnerships with 1st PhileKorea, South Korea, As One Corporation, Japan, Decode Science, Australia and New Zealand, Everlife Research Instruments, Singapore, and Premas Life Sciences, India and Bangladesh. These additions join Sphere Bio’s existing network of distributors, which includes Bang Trading, Thailand, Cold Spring Biotech, Taiwan, and Gene Company, China and Hong Kong.

According to the company, the expansion is part of a wider commercial strategy to improve access to its technologies and strengthen local technical support in high-growth markets. The move follows recent product developments, including the launch of its Cyto-Mine Chroma platform and new assay tools for functional single-cell analysis.

Dale Levitzke, CEO of Sphere Bio, said the company is scaling operations to support international growth. “We’ve identified strong partners in the region to meet increasing demand and improve customer support,” he said.

Jay Manikandan, VP Commercial (APAC), added that the expanded network will improve the company’s ability to work with local researchers and technical teams.

Inside Sphere Bio’s APAC strategy

Q: Why focus on Asia-Pacific now?

A: According to Sphere Bio, the region represents some of the fastest-growing markets for advanced cell analysis tools. Expanding local distribution is intended to improve product access and technical support.

Q: What’s different about these new partnerships?

A: The five new distributors were selected for their reach and experience in life sciences. The company says this will help deliver both commercial reach and specialist support across local research communities.

Q: How does this tie into Sphere Bio’s wider strategy?

A: The expansion is part of a global scale-up following new product launches, including Cyto-Mine® Chroma. Sphere Bio says it aims to increase adoption of its single-cell platforms through regional investment.

Q: What are researchers asking for in this space?

A: The company cites rising demand for high-throughput, functional single-cell analysis tools that are adaptable and easy to integrate into lab workflows.